Opciones de tratamiento farmacológico actuales y futuras en la artritis psoriásica

Revista Espanola de Reumatologia

Volumn 28, Issue 9, 2001, Pages 382-386

  Torre Alonso, Juan Carlos ^a  

^a HOSPITAL MONTE NARANCO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29344459838     PISSN: 03044815     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Alibert JL. Précise theorique et practique sur les maladies de la peau. París: Caille et Ravier, 1818.
2. a ed.). Londres: Kimpton, 1960; 20-21.
3. Baker H, Golding DN, Thompson M. Psoriasis and arthritis. Ann Intern Med 1963; 58: 909-925.
4. Baker H. Epidemiological aspects of psoriasis and arthritis. Br J Dermatol 1966; 78: 249-261.
5. Wright V. Psoriasis and arthritis. Ann Rheum Dis 1956; 15: 348-356.
6. Jajic I. Radiological changes in sacroiliac joints and spine of patients with arthritis and psoriasis. Ann Rheum Dis 1968; 27: 1-6.
7. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheumatism 1973; 3: 55-78.
8. Scarpa R, Oriente P, Pucino A, Torrella M, Vignone L, Riccio A et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984; 23: 246-250.
9. O'Neill TO, Silman AJ. Psoriatic arthritis: historical background and epidemiology. Baillíeres Clin Rheumatol 1994; 8: 245-261.
10. Winchester R. Psoriatic arthritis. Dermatol Clin 1995; 13: 779-792.
11. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years old. Arthritis Rheum 1999; 42: 1080-1086.
12. Tassiulas I, Duncan SR, Centola M, Theofilo-Poulos AN, Boumpas DT. Clonal characteristics on T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999; 60: 479-491.
13. Torre-Alonso JC, Rodríguez-Pérez A, Arribas-Castrillo JM, Ballina García J, Riestra Noriega JL, López Larrea et al. Psoriatic arthritis (PA): a clinical immunologic and radiological study. Br J Rheumatol 1991; 30: 245-250.
14. Gladman DD, Shuckm R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis - clinical and laboratory analysis of 220 patients. Q J Med 1987; 62: 127-141.
15. Gladman DD, Farewell VT, Kopciuk K, Cook RJ. HIA antigens and progression in psoriatle arthritis. J Rheumatol 1998; 25: 730-733.
16. Lience E. Tratamiento de la arthritis psoriásica. Rev Esp Reumatol 1997; 24: 374-378.
17. Kay L, Walker D. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheumatol 1998; 37: 234-235.
18. Gladman DD, Farewell VT. Progresion in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 1999; 26: 2409-2413.
19. Buskila D, Iangevitz P, Gladman DD, Urowitz S, Smythe H. Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J Rheumatol 1992; 19: 1115-1119.
20. Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI et al. A multi-centre doubleblind comparison of auranofin, intra-muscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990; 29: 280-283.
21. Mader R, Gladman DD, Long J, Gough J, Farewell VT. Injectable gold for the treatment of psoriatic arthritis (PsA) - long-term follow up. Clin Invest Med 1995; 18: 139-143.
22. Carette S, Calin A, McCafgferty JP, Wallin BA and the Auranofin Cooperative Group. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arhtritis Rheum 1989; 32: 158-165.
23. Kamer GM, Sotter NA, Gibson TJ, Schur PH. Psoriatic arthritis: a clinical, inmunological and HLA study of 100 patients. Semin Arthritis Rheum 1979; 9: 75-97.
24. Black RL, O'Brien WM, Van Scott EJ, Auerbach R, Eisen AZ, Bunim JK. Methotrexate therapy in psoriatic arthritis. Double blind study on 21 patients. JAMA 1964; 189: 743-747.
25. Wilkens RF, Williams J, Ward JR Eger MJ, Reading JG, Clements PJ et al. Randomized double blind placebo-controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27: 376-381.
26. Zacharias H, Zacharias E. Methotreaxate treatment of psoriatic arthritis. Acta Derm Venereol 1987; 67: 270-273.
27. Espinoza LR, Zakraoni L, Espinoza CG, Gutiérrez F, Jara JL, Silveira LH et al. Psoriatic arthritis: clinical response and side effects of methotrexate therapy. J Rheumatol 1992; 19: 872-877.
28. Abu-Shakra M, Gladman D, Thorne JC, Long J, Gough J, Farewell VT et al. Long-term methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol 1995; 22: 241-245.
29. Dougados M, Van der Linden S, Leirisalo Repo M, Huitfeldt B, Juhlin R, Veys E et al. Sulphasalazine in the treatment of spondyloarthropathy and randomized, multicenter double-blind placebo-controlled study. Arthritis Rheum 1995; 38: 618-627.
30. Clegg DO, Reda DJ, Mejías E, Cannon GW, Weirman MH, Taylor T et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-2020.
31. Rahman P, Gladman DD, Zhou Y, Cook RJ. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998: 25: 1957-1961.
32. Combe B, Goupille P, Kuntz JL, Tebib J, Liote F, Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized, multi-centre, placebo-controlled study. Br J Rheumatol 1996; 35: 664-668.
33. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhess JJ et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995; 22: 894-898.
34. Steinsson K, Jonsdomr I, Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 1990; 49: 603-606.
35. Pioro MH, Cash JM. Treatment of refractory psoriatic arthritis. Rheum Dis Clin North Am 1995; 21: 129-149.
36. Spadarao A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zappini A. Comparison of cyclospory A and Methotrexate in treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995; 13: 589-593.
37. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G et al. A comparation of cyclosporine, sulfasalazine and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28: 2274-2282.
38. Klinkhoff AV, Gertner E, Chalmers A, Gladman DD, Stewart WD, Schachater GD et al. Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989; 16: 789-791.
39. Starcher B. Role of tumor necrosis factor alpha receptors in ultraviolet-induced skin tumours. Br J Dermatol 2000; 142: 1140-1147.
40. Partsch G, Steiner G, Lfeb BF , Dunky A, Broll H, Smolen JS et al. Highly increased levels of tumor necrosis factor-α and other pro-inflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-523.
41. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H et al. Use of inmunohistologic and in situ hybridization techniques in the examination of sacroiliac joints biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499-505.
42. Mease P, Goffe B, Metz J, Vanderstoep A, Finck B, Burge DJ. Etarnercept in the treatment psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390.
43. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe resistant psoriatic arthritis. Arthritis Rheum 1999; 42 (Supl 9): 379.
44. Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy. An open pilot study. Ann Rheum Dis 2000; 59: 428-433.
45. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C et al. Immunomodulatory effects of anti-tumour necrosis factor alpha therapy in sinovium in spondyloarthropathy: histologic findings in 8 patients from an open label pilot study. Arthritis Rheum 2001; 44: 186-195.
46. Antoni C, Dechant C, Lorenz H, Olgivie A, Kalden-Nemeth D, Kalden J. Successful treatment of severe psoriatic arthritis with infliximab. Arthritis Rheum 1999; 42 (Supl. 9): 371.